Article Summary: KS and lymphoma rates were highest immediately after ART initiation particularly among patients with low CD4 cell counts, while other cancers increased with time on ART. Calendar year of ART initiation was not associated with subsequent cancer incidence.
Introduction
While the distribution of cancer types within HIV-infected populations has changed due to advances in treatment and demographic changes, malignancies remain an important cause of morbidity and mortality [1] [2] [3] [4] . Cancer incidence trends in the HIV population have been thoroughly examined across calendar time [1, [5] [6] [7] . However, incidence rates among HIV patients are not well-described across time relative to initiation of combination antiretroviral therapy (ART), even though most cancers in developed countries are diagnosed after ART initiation [8] [9] [10] .
Given the many changes that can occur after ART initiation, including immune reconstitution, HIV replication, aging, and ongoing exposure to carcinogens, cancer incidence over time following ART initiation is expected to be dynamic. Additionally, improvements in access to HIV testing and linkage to care as well as changes in the timing of ART initiation may impact the timing and incidence of cancer diagnoses in treated patients. In a large, diverse U.S. cohort of HIV-infected patients in care, the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS), we evaluated trends in cancer incidence rates over time after ART initiation to inform cancer screening and prevention efforts for the HIV population in the ART era. We further identified patient characteristics associated with these trends that may provide insights into the etiology of cancers occurring in HIV-infected populations.
Methods

Study Population
We conducted this study in the CNICS cohort, which includes over 25,000 HIV-infected adults in routine care at eight university-affiliated CFARs from 1995 to the present. The methodology and characteristics of the CNICS cohort are described in detail elsewhere [11] .
Briefly, CNICS is a dynamic observational cohort with approximately 1400 new patients by Jules Levin on June 24, 2013 http://cid.oxfordjournals.org/
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A c c e p t e d M a n u s c r i p t 4 enrolling and 13% of existing patients leaving care each year. CNICS captures extensive and comprehensive electronic medical data, including demographics, medications, co-morbid diagnoses, and laboratory values [11] . Diagnoses of cancer are verified through a standardized process, including detailed record abstraction and adjudication of malignancies [12] .
For our study, we included patients who initiated ART with a known start date between Jan. 1, 1996-Aug. 30, 2011, and had a CD4 count and HIV RNA measurement at ART initiation.
Baseline CD4 count and HIV RNA measures were the values most proximal to, but no more than 12 months before, ART initiation. ART was defined as concurrent initiation of at least three different antiretrovirals. For our primary analyses, we included patients with prior exposure to one or two nucleoside/nucleotide agents (mono-and dual-antiretroviral therapy, respectively) or who had an unknown antiretroviral history prior to initiating ART. We did not analyze persontime prior to ART initiation; however, we did assess effects of prior therapy exposure on our results, and conducted sensitivity analyses in which only antiretroviral-naïve patients at ART initiation were included.
Patients were followed from ART initiation to the first of the following: cancer diagnosis, death, loss-to-follow-up (defined as 12 months without a clinical visit), or administrative censoring at the last date of cancer ascertainment for each clinic site (range of May 31, 2010-Aug. 31, 2011). Follow-up time was administratively censored at 10 years after ART initiation, at which point <10% of the patients remained under observation. Only the first cancer diagnosis after ART initiation was included as an event. In our primary analyses we included all patients initiating ART without regard to cancer events prior to ART initiation. To assess the influence of including patients with a previous history of cancer, we performed sensitivity analyses in which patients with cancer diagnoses prior to ART initiation were excluded. 
Statistical Analysis
Incidence rates (IRs) were estimated as the total number of cancer diagnoses within a time interval divided by the total number of person-years contributed within the same interval.
Overall cancer incidence rates and incidence rates within 6-month and 1-year time intervals following ART initiation were calculated for specific cancers as well as for clinically meaningful pre-defined groups of cancers. Specifically, we assessed incidence rates using different categorizations including: AIDS-defining cancers (ADCs) (including Kaposi sarcoma (KS), nonHodgkin lymphoma, and cervical cancer), non-AIDS-defining cancers (NADCs), lymphomas, HPV-related cancers (including cervical, anal, squamous cell oral cavity/pharynx, vagina/vulva, and penis cancer), virus-related cancers (including all ADCs, all HPV-related cancers, Hodgkin lymphoma, and liver cancer), and virus-unrelated cancers.
Poisson regression was used to contrast incidence rates between time intervals and to estimate trends in incidence rates across time following ART initiation. Baseline clinical characteristics were examined with Cox regression to identify predictors of cancer incidence following ART initiation. Cancers were grouped by common etiology and similar incidence patterns over time when assessing associations with baseline characteristics. Multivariable analyses were conducted with adjustment for all baseline demographic and clinical predictors determined to be associated with cancer incidence based on a priori knowledge. Two separate adjustment sets were used: one with CD4 count at ART initiation, and one with nadir CD4 count any time prior to ART. These two variables were not included simultaneously as they were highly correlated, but were included separately to examine whether choice of CD4 measure affected other estimates differentially, especially for patients with prior antiretroviral exposure.
Incidence rates across time were also stratified by CD4 count at ART initiation (≥ or <200 cells/mm these predictors with cancer incidence were assessed visually, and through the evaluation of interaction terms with log(time) in regression models.
Results
Baseline Characteristics
Of 25,337 patients enrolled in CNICS at the time of this analysis, 11,485 were observed to initiate ART between 1996 and 2011 at a CNICS site with pre-ART CD4 count and HIV RNA levels available. Of these 11,485 patients, 20% were female, 43% were white, 41% black, and 11% Hispanic (Table 1) 
Cancer Incidence and Timing
During the 46,318 person-years of follow-up after ART initiation, 457 cancer diagnoses were observed with an IR of 987 cases per 100,000 person-years (95% Confidence Interval
[CI]: 900-1081) ( Table 2 ). The overall incidence of ADCs was similar to that of NADCs (ADC IR: 
Predictors of Cancer Incidence and Time-Modification of Predictors
Several characteristics at the time of ART initiation were associated with subsequent cancer incidence. Older age increased risk for all cancers except KS in bivariable analyses, and associations appeared the same in multivariable analyses (Table 3) . Non-lymphoma, HPVunrelated NADCs were most strongly associated with older age (adjusted hazard ratio [HR] for were consistent throughout time following ART initiation (P for interaction with time>0.05 for all cancers) (Figure 2 ).
CD4 count at ART initiation was also an independent predictor of cancer. In both bivariable and multivariable analyses, lower CD4 count was associated with higher incidence of all cancer groups except the non-lymphoma, HPV-unrelated NADCs. Lower CD4 count was a particularly strong predictor of KS (Adjusted HR per 100 cells/mm 3 increase: 0.63, 95%CI: 0.54-0.73). The pattern of a high incidence of KS within the first six months followed by a steep decline was only seen among those with a CD4 count <200 cells/mm 3 at ART initiation ( Figure   2 , P for interaction of CD4 count with time=0.002). By contrast, those with a CD4 count ≥200 cells/mm 3 had low incidence of KS throughout time after ART initiation (IR: 0.1 per 100 personyears, 95%CI: 0.1-0.2). Low CD4 count was also associated with high incidence of lymphomas and HPV-related cancers, but for these cancers, associations with CD4 count were consistent across time (both P for interaction with time>0.20) (Figure 2 ).
Prior exposure to antiretrovirals was associated with higher incidence of HPV-related cancer following ART initiation. This association persisted even when nadir CD4 count was included in the model in place of CD4 count at ART initiation. Across all follow-up time, prior antiretroviral exposure was not associated with incidence of other cancers. However, patients with prior antiretroviral exposure had a lower incidence of lymphoma compared to antiretroviral naïve patients in the first year following ART initiation (Adjusted HR: 0.41, 95%CI: 0.19-0.93), but a higher incidence after one year (P for interaction with time<0.05) (Figure 3 ).
Other characteristics examined were weaker predictors of cancer incidence. Higher level of HIV RNA pre-ART was associated with higher KS incidence after adjusting for CD4 count, but not with any other cancer. No statistically significant associations were found between calendar year of ART initiation and incidence of any cancer in bivariable analysis. After accounting for variables such as age and CD4 count at ART initiation, there was no association between calendar year and any cancer ( Table 3 ). The lack of association was robust to parameterization of calendar year as a continuous or categorical variable.
In sensitivity analysis where 489 patients with cancer diagnoses prior to ART initiation were excluded, similar incidence rates and incidence trends were observed and the same predictors of cancer incidence were identified (data not shown). Similarly, our findings were consistent in a subset analysis conducted among 8278 patients who were antiretroviral naïve at ART initiation. In this subset, cancer incidence rates and trends were similar to the full study population and factors associated with higher risk were also consistent in both unadjusted and adjusted analyses (data not shown).
Discussion
This study of 11,485 patients from a multi-site U.S. clinical cohort of HIV-infected patients revealed distinct patterns of cancer incidence following ART initiation. This likely reflects varying etiologic contributions of aging, immunosuppression, and prior antiretroviral exposure, to the occurrence of specific cancer types. By contrast, cancer incidence did not appear to change over calendar time among ART initiators suggesting that the incremental improvements in ART regimens during the modern ART era have not had dramatic effects on cancer incidence.
The most dramatic change in incidence after ART initiation was seen for KS, which had a higher incidence than all other cancers combined in the first six months and a steep decline thereafter. Notably, this pattern was seen exclusively in those initiating ART with a CD4 count <200 cell/mm 3 . A similar pattern has been noted in ART initiators in the Swiss HIV Cohort Study [13] . The HIV/AIDS Cancer Match Study found that severe immunosuppression at AIDS diagnosis was strongly associated with risk of a new KS diagnosis in the 4-9 months after AIDS diagnosis and less strongly thereafter [14] . This finding and prior research demonstrating higher KS incidence among those with lower current CD4 counts [8, [15] [16] [17] are consistent with an early risk driven by more severe immunosuppression. In addition to severe immunosuppression increasing the risk of KS development, these individuals are more likely to experience more rapid immune reconstitution that may unmask previously subclinical KS, a phenomenon referred to as immune reconstitution inflammatory syndrome (IRIS) [18] [19] [20] [21] .
Lymphomas showed a pattern similar to KS, but with a lower incidence in the first six months and a more gradual decrease in incidence thereafter. A decrease in incidence after six months was seen for both non-Hodgkin lymphoma and Hodgkin lymphoma. Individuals with no prior antiretroviral exposure and those with lower CD4 counts at ART initiation had higher lymphoma incidence within the first six months. Similar to KS, these patient groups may be more likely to develop lymphoma associated IRIS events after ART initiation. An IRIS effect for lymphoma was hypothesized after a study in France showed a similar incidence pattern when looking at Hodgkin lymphoma after ART [22] . It is also possible that early symptoms of subclinical KS or lymphoma may have led to the diagnosis of HIV and prompt initiation of ART, with documentation of the definitive cancer diagnosis shortly after starting ART. While 1 lymphoma and 9 KS cases were observed within the first week after ART initiation, these early cases do not completely account for the higher incidence in the first six months. Regardless, these findings highlight the importance of early HIV diagnosis and timely ART initiation before individuals reach advanced immunosuppression.
All other cancers combined showed an increasing trend over time following ART initiation with a lower incidence within the first six months and a significant trend toward higher incidence over time. This increase is likely a consequence of increasing cancer incidence with advancing age, as noted in the general population. Within this group of cancers that excluded KS and lymphoma, HPV-related cancers showed a strong association with CD4 count at ART initiation and higher incidence in those with prior ARV exposure, which may reflect longer occur before the increased risk is manifest as increased cancer diagnosis rates in patients with a longer duration of HIV infection [23] [24] [25] [26] . It is also possible that adjustment for nadir CD4, a risk factor for HPV-associated cancers [7, 9, 26, 27] , was inadequate if patients with prior antiretroviral exposure experienced their nadir CD4 before entry into a CNICS clinic. We did not observe an association between CD4 count at ART initiation and incidence of cancers that are neither AIDS-defining or associated with viral infections. Others have shown some virusunrelated NADCs to be associated with the extent of immune suppression [16, 28] . A larger sample size may be needed to observe an association between low CD4 count and virusunrelated NADCs; however, our data suggest that the relationship is not particularly strong.
Previous studies have described changing trends in cancer incidence within the HIV population as a whole [5, 7, 29] ; however, in our population of ART initiators no changes in This study was notable for the following strengths: a) a large and representative HIVinfected clinical population; b) detailed laboratory and antiretroviral information; and c) wellvalidated cancer diagnoses. The current study does not account for changes or discontinuations in ART after initiation nor does it account for differences in the immunologic or virologic response to ART. In a future study we will examine how these changes after ART initiation may impact cancer incidence to expand on these findings and further our understanding of cancer incidence trends over time in this population.
We showed distinct patterns of cancer incidence after ART initiation that differed by cancer type and were modified by several baseline patient characteristics. These findings among those with prior exposure to mono or dual-therapy or an unknown antiretroviral history at ART initiation. *Other cancers include lung, liver, prostate, breast, melanoma, colorectal, kidney, bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, stomach, testicular, uterus, or non-squamous cell oral cavity/pharynx.
